Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

October 31, 2029

Conditions
Small-cell Lung Cancer
Interventions
PROCEDURE

Thoracic radiotherapy

30Gy/10 fractions thoracic radiotherapy given between 2nd and 3rd course of chemo-immunotherapy.

DRUG

Chemo-immunotherapy

Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.

Trial Locations (20)

Unknown

RECRUITING

North Estonia Medical Centre, Tallinn

RECRUITING

Landspitali University Hospital, Reykjavik

RECRUITING

Erasmus MC, Rotterdam

RECRUITING

Ålesund Hospital, Ålesund

RECRUITING

Haukeland Universitetssykehus, Bergen

RECRUITING

Nordlandssykehuset HF, Bodø

RECRUITING

Drammen sykehus - Vestre Viken, Drammen

RECRUITING

Innlandet hospital Gjøvik, Gjøvik

RECRUITING

Haugesund hospital, Haugesund

RECRUITING

Sykehuset Levanger, Levanger

RECRUITING

Akershus Universitetssykehus AHUS, Oslo

RECRUITING

Oslo University Hospital Ullevål, Oslo

RECRUITING

Stavanger University Hospital, Stavanger

RECRUITING

University Hospital of North Norway, Pulmonology Department, Tromsø

RECRUITING

Cancer Clinic at St. Olavs Hospital, Trondheim

RECRUITING

Gävle hospital, Gävle

RECRUITING

Sahlgrenska Sjukehuset, Gothenburg

RECRUITING

Linköping University Hospital, Linköping

RECRUITING

Lund University Hospital, Skåne

RECRUITING

Karolinska University Hospital, Stockholm

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

collaborator

Alesund Hospital

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

Oslo University Hospital

OTHER

collaborator

Helse Nord-Trøndelag HF

OTHER

collaborator

Helse Fonna

OTHER

collaborator

Drammen sykehus

OTHER

collaborator

University Hospital, Akershus

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Karolinska University Hospital

OTHER

collaborator

Gävle Hospital

OTHER

collaborator

Sykehuset Innlandet HF

OTHER

collaborator

North Estonia Medical Centre

OTHER

collaborator

Nordlandssykehuset HF

OTHER

collaborator

Landspitali University Hospital

OTHER

collaborator

Lund University Hospital

OTHER

collaborator

University Hospital, Linkoeping

OTHER

lead

Norwegian University of Science and Technology

OTHER

NCT05223647 - Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer | Biotech Hunter | Biotech Hunter